Retrospective Study on the Therapeutic Effects of an Etoposide, Adriamycin, Cisplatin-II (EAP- II) versus an Etoposide, Leucovorin, 5-Furorouracil (ELF) Combination Chemotheraphy in Unresectable Gastric Cancer
Journal of the Korean Gastric Cancer Association
;
: 122-127, 2003.
Article
in Korean
| WPRIM
| ID: wpr-132072
ABSTRACT
PURPOSE:
The incidence rate and the mortality rate of gastric cancer have decreased in developed countries over the last several decades. On the other hand, they remain high in far eastern countries such as Korea, Japan, China and in many developing countries. The cure of patients with gastric carcinomas can be achieved mostly through complete surgical resection, but most gastric cancer patients are in advanced stages when diagnosed and have poor prognoses. therefore, the development of an effective systemic therapy is essential for far advanced gastric cancer patients. Until recently, the most commonly used combination chemotherapy was based on 5-flurouracil or cisplatin, but the results were not satisfactory, so recently etoposide, adriamycin and cisplatin (EAP-II) combination chemotherapy was introduced in patients with advanced gastric cancer. Early studies showed a high response rate and the ability to convert unresectable cases to resectable ones, but later studies couldn`t duplicate the result. the purpose of this study was to evaluate the relative efficacy&toxicity of EAP-II chemotherapy and ELF chemotherapy which is based on 5-flurouracil. MATENRIALS ANDMETHODS:
Between July 1992 and July 2002, sixty-five patients with inoperable advanced gastric cancer were enrolled for this study. Thirty-seven patient received EAP-II chemotherapyetoposide (20 mg/m2 IV for 1~5 days), adriamycin (20 mg/m2 IV for 1~5 days) and cisplatin (20 mg/m2 IV for 1~5 days) and Twenty-eight patients receieved ELF chemotherapyetoposide (100 mg/m2 IV for 1~3 days), leucovorin (20 mg/m2 IV for 1~5 days) and 5-FU (500 mg/m2 IV for 1~5 days). Each treatment schedule for each group was repeated every four weeks EAP-II means 3.4 cycles per patient ELF means 4.1 cycles per patientRESULTS:
Total respones rates were 5.4% in the ELF group and 3.6% in the EAP group (P-value>0.05). The median times to progression were 144 days in the ELF group and 92 days in the EAP-II group (P-value>0.05), and the median overall survival times were 189 days in the ELF group and 139 days in the EAP-II group (P-value>0.05). The difference in the survival curves for the two regimens was not statistically significant. Non-hematologic toxicitis&hematologic toxicitis were more frequently observed for the EAP-II regimen. Anemia 27.6% in ELF vs 54% in EAP-II; Leukopenia 8.5% in ELF vs 19% in EAP-II; nausea&vomiting 45.9% in ELF vs 67.8% in EAP-II.CONCLUSION:
EAP-II regimen is not superior to ELF regimen in the tratment of inoperable advanced gastric cancer.
Full text:
Available
Index:
WPRIM (Western Pacific)
Main subject:
Appointments and Schedules
/
Prognosis
/
Stomach Neoplasms
/
Doxorubicin
/
Developed Countries
/
China
/
Leucovorin
/
Incidence
/
Retrospective Studies
/
Mortality
Type of study:
Incidence study
/
Observational study
/
Prognostic study
Limits:
Humans
Country/Region as subject:
Asia
Language:
Korean
Journal:
Journal of the Korean Gastric Cancer Association
Year:
2003
Type:
Article
Similar
MEDLINE
...
LILACS
LIS